Alembic Pharmaceuticals surges after getting EIR from USFDA for Oral Solid Formulation Facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Alembic Pharmaceuticals is currently trading at Rs. 1205.45, up by 12.80 points or 1.07% from its previous closing of Rs. 1192.65 on the BSE.
The scrip opened at Rs. 1204.95 and has touched a high and low of Rs. 1248.95 and Rs. 1184.75 respectively. So far 28472 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1248.95 and Rs. 1117.55 respectively. The current market cap of the company is Rs. 23734.01 crore.
The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 19.79% and 10.60% respectively.
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its Oral Solid Formulation Facility (F-I) at Panelav from July 17, 2024 to July 26, 2024. With this, for all the company’s USFDA facilities, EIRs are in place.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
